Skip to main content

Table 10 Sensitivity analysis results for a time horizon of 2 years: variation of prevalence and costs

From: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis

 

Additional tests** versus Aptima, n = 

Additional costs versus Aptima, €

Lower values for costs* (− 25%) and prevalence (10.5%)

Hybrid Capture® 2

265,652

283,277,525.29 €

Cobas® 4800

276,698

2,294,970.33 €

Higher values for costs* (+ 25%) and lower value for prevalence (10.5%)

Hybrid Capture® 2

265,652

442,621,133.27 €

Cobas® 4800

276,698

3,585,891.13 €

Lower values for costs* (− 25%) and higher value for prevalence (25.4%)

Hybrid Capture® 2

243,924

432,074,832.70 €

Cobas® 4800

230,360

1,910,159.13 €

Higher values for costs* (+ 25%) and prevalence (25.4%)

Hybrid Capture® 2

243,924

675,116,926.10 €

Cobas® 4800

230,360

2,984,623.65 €

  1. *Includes cytology, colposcopy, and biopsy
  2. **Includes HPV tests and other diagnostic tests (cytology, colposcopy, and biopsy)
  3. Includes the cost of HPV genotyping after the first and subsequent Hybrid Capture® 2 tests